RE:RE:RE:Updated time lineAgain, we all knew they were slower than expected in the phase Ia, and now, maybe that reached a higher dose than really expected, or they reached their best case scenario which is three times the MTD of docetaxel alone. All that being said, nothing has changed on the communication timelines. In an article in the Montreal newspaper La Presse on October 13, it is stated this: "Theratechnologies will update the first part of the Phase 1 trial again when it finds the maximum tolerated dose of the drug. Company plans to move to the second part of the Phase 1 trial in the first quarter of 2022"
Again, if it goes in February or March, I expect the company to update the market about it with reitarating that the MTD is not reached yet and telling at what dose they are. I expect it because even though they said they would update when the MTD would be reached, they also always said that it would be, at the latest, at the begining of 2022. So if it is to go beyond that, they should update the market. That being said, I don't expect efficacy data until the end of phase Ia.